These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30898550)

  • 1. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.
    Selim M; Foster LD; Moy CS; Xi G; Hill MD; Morgenstern LB; Greenberg SM; James ML; Singh V; Clark WM; Norton C; Palesch YY; Yeatts SD;
    Lancet Neurol; 2019 May; 18(5):428-438. PubMed ID: 30898550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT.
    Sprigg N; Flaherty K; Appleton JP; Al-Shahi Salman R; Bereczki D; Beridze M; Ciccone A; Collins R; Dineen RA; Duley L; Egea-Guerrero JJ; England TJ; Karlinski M; Krishnan K; Laska AC; Law ZK; Ovesen C; Ozturk S; Pocock SJ; Roberts I; Robinson TG; Roffe C; Peters N; Scutt P; Thanabalan J; Werring D; Whynes D; Woodhouse L; Bath PM
    Health Technol Assess; 2019 Jul; 23(35):1-48. PubMed ID: 31322116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods.
    Yeatts SD; Palesch YY; Moy CS; Selim M
    Neurocrit Care; 2013 Oct; 19(2):257-66. PubMed ID: 23943316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Desborough MJR; Al-Shahi Salman R; Stanworth SJ; Havard D; Woodhouse LJ; Craig J; Krishnan K; Brennan PM; Dineen RA; Coats TJ; Hepburn T; Bath PM; Sprigg N;
    Lancet Neurol; 2023 Jul; 22(7):557-567. PubMed ID: 37353276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
    Meretoja A; Yassi N; Wu TY; Churilov L; Sibolt G; Jeng JS; Kleinig T; Spratt NJ; Thijs V; Wijeratne T; Cho DY; Shah D; Cloud GC; Phan T; Bladin C; Moey A; Aviv RI; Barras CD; Sharma G; Hsu CY; Ma H; Campbell BCV; Mitchell P; Yan B; Parsons MW; Tiainen M; Curtze S; Strbian D; Tang SC; Harvey J; Levi C; Donnan GA; Davis SM
    Lancet Neurol; 2020 Dec; 19(12):980-987. PubMed ID: 33128912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial.
    Yassi N; Zhao H; Churilov L; Wu TY; Ma H; Nguyen HT; Cheung A; Meretoja A; Mai DT; Kleinig T; Jeng JS; Choi PMC; Duc PD; Brown H; Ranta A; Spratt N; Cloud GC; Wang HK; Grimley R; Mahawish K; Cho DY; Shah D; Nguyen TMP; Sharma G; Yogendrakumar V; Yan B; Harrison EL; Devlin M; Cordato D; Martinez-Majander N; Strbian D; Thijs V; Sanders LM; Anderson D; Parsons MW; Campbell BCV; Donnan GA; Davis SM;
    Lancet Neurol; 2024 Jun; 23(6):577-587. PubMed ID: 38648814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.
    Hanley DF; Thompson RE; Rosenblum M; Yenokyan G; Lane K; McBee N; Mayo SW; Bistran-Hall AJ; Gandhi D; Mould WA; Ullman N; Ali H; Carhuapoma JR; Kase CS; Lees KR; Dawson J; Wilson A; Betz JF; Sugar EA; Hao Y; Avadhani R; Caron JL; Harrigan MR; Carlson AP; Bulters D; LeDoux D; Huang J; Cobb C; Gupta G; Kitagawa R; Chicoine MR; Patel H; Dodd R; Camarata PJ; Wolfe S; Stadnik A; Money PL; Mitchell P; Sarabia R; Harnof S; Barzo P; Unterberg A; Teitelbaum JS; Wang W; Anderson CS; Mendelow AD; Gregson B; Janis S; Vespa P; Ziai W; Zuccarello M; Awad IA;
    Lancet; 2019 Mar; 393(10175):1021-1032. PubMed ID: 30739747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial.
    Sprigg N; Flaherty K; Appleton JP; Al-Shahi Salman R; Bereczki D; Beridze M; Christensen H; Ciccone A; Collins R; Czlonkowska A; Dineen RA; Duley L; Egea-Guerrero JJ; England TJ; Krishnan K; Laska AC; Law ZK; Ozturk S; Pocock SJ; Roberts I; Robinson TG; Roffe C; Seiffge D; Scutt P; Thanabalan J; Werring D; Whynes D; Bath PM;
    Lancet; 2018 May; 391(10135):2107-2115. PubMed ID: 29778325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelators for acute stroke.
    Van der Loo LE; Aquarius R; Teernstra O; Klijn K; Menovsky T; van Dijk JMC; Bartels R; Boogaarts HD
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009280. PubMed ID: 33236783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Peter-Derex L; Philippeau F; Garnier P; André-Obadia N; Boulogne S; Catenoix H; Convers P; Mazzola L; Gouttard M; Esteban M; Fontaine J; Mechtouff L; Ong E; Cho TH; Nighoghossian N; Perreton N; Termoz A; Haesebaert J; Schott AM; Rabilloud M; Pivot C; Dhelens C; Filip A; Berthezène Y; Rheims S; Boutitie F; Derex L
    Lancet Neurol; 2022 Sep; 21(9):781-791. PubMed ID: 35963261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial.
    Foster L; Robinson L; Yeatts SD; Conwit RA; Shehadah A; Lioutas V; Selim M;
    Stroke; 2022 Jul; 53(7):2204-2210. PubMed ID: 35306827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.
    Ma L; Hu X; Song L; Chen X; Ouyang M; Billot L; Li Q; Malavera A; Li X; Muñoz-Venturelli P; de Silva A; Thang NH; Wahab KW; Pandian JD; Wasay M; Pontes-Neto OM; Abanto C; Arauz A; Shi H; Tang G; Zhu S; She X; Liu L; Sakamoto Y; You S; Han Q; Crutzen B; Cheung E; Li Y; Wang X; Chen C; Liu F; Zhao Y; Li H; Liu Y; Jiang Y; Chen L; Wu B; Liu M; Xu J; You C; Anderson CS;
    Lancet; 2023 Jul; 402(10395):27-40. PubMed ID: 37245517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial.
    Hanley DF; Lane K; McBee N; Ziai W; Tuhrim S; Lees KR; Dawson J; Gandhi D; Ullman N; Mould WA; Mayo SW; Mendelow AD; Gregson B; Butcher K; Vespa P; Wright DW; Kase CS; Carhuapoma JR; Keyl PM; Diener-West M; Muschelli J; Betz JF; Thompson CB; Sugar EA; Yenokyan G; Janis S; John S; Harnof S; Lopez GA; Aldrich EF; Harrigan MR; Ansari S; Jallo J; Caron JL; LeDoux D; Adeoye O; Zuccarello M; Adams HP; Rosenblum M; Thompson RE; Awad IA;
    Lancet; 2017 Feb; 389(10069):603-611. PubMed ID: 28081952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
    Klopstock T; Tricta F; Neumayr L; Karin I; Zorzi G; Fradette C; Kmieć T; Büchner B; Steele HE; Horvath R; Chinnery PF; Basu A; Küpper C; Neuhofer C; Kálmán B; Dušek P; Yapici Z; Wilson I; Zhao F; Zibordi F; Nardocci N; Aguilar C; Hayflick SJ; Spino M; Blamire AM; Hogarth P; Vichinsky E
    Lancet Neurol; 2019 Jul; 18(7):631-642. PubMed ID: 31202468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.
    Ginsberg MD; Palesch YY; Hill MD; Martin RH; Moy CS; Barsan WG; Waldman BD; Tamariz D; Ryckborst KJ;
    Lancet Neurol; 2013 Nov; 12(11):1049-58. PubMed ID: 24076337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.
    Baharoglu MI; Cordonnier C; Al-Shahi Salman R; de Gans K; Koopman MM; Brand A; Majoie CB; Beenen LF; Marquering HA; Vermeulen M; Nederkoorn PJ; de Haan RJ; Roos YB;
    Lancet; 2016 Jun; 387(10038):2605-2613. PubMed ID: 27178479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.
    van den Berg SA; Uniken Venema SM; Reinink H; Hofmeijer J; Schonewille WJ; Miedema I; Fransen PSS; O Pruissen DM; Raaijmakers TWM; van Dijk GW; de Leeuw FE; van Vliet JA; Kwa VIH; Kerkhoff H; van 't Net A; Boomars R; Siegers A; Lok T; Caminada K; Esteve Cuevas LM; Visser MC; Zwetsloot CP; Boomsma JMF; Schipper MH; van Eijkelenburg RPJ; Berkhemer OA; Nieboer D; Lingsma HF; Emmer BJ; van Oostenbrugge RJ; van der Lugt A; Roos YBWEM; Majoie CBLM; Dippel DWJ; Nederkoorn PJ; van der Worp HB;
    Lancet Neurol; 2022 Nov; 21(11):971-981. PubMed ID: 36058230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.